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he quantitative and qualitative production of the collagen phenotype is among the important functions of vascular smooth muscle cells (SMCs; 1, 2). The vascular extracellular matrix contains an abundance of fibrillar collagen I and III, as well as a small amount of fibrillar collagen V, which plays a crucial role in regulating the architecture of heterotypic collagen fibrils (3). Precise modulation of the fibrillar collagen-type ratio is essential to normal vascular tissue function. During atherosclerosis development, vascular SMCs lose their ability to contract and migrate from the media to the intima. After several divisions, they synthesize and deposit the components of the fibrotic plaque, which are mainly collagens (4, 5).
Because cultured vascular SMCs show alterations similar to those seen in atherosclerosis (2, 6), they are useful for investigating excessive production of extracellular matrix collagens by SMCs (7-10). The accumulation of collagens in fibrotic plaque in vivo or in post-confluent SMCs in vitro may be sensitive to endogenous and exogenous growth factors (7, 11). In particular, FGF-2 and TGF-β1 influence SMC behavior (12, 13) and are involved in the differential regulation of the collagen phenotype. Interestingly, FGF-2 selectively decreased collagen III production by SMCs (14), whereas TGF-β1 preferentially stimulated collagen V synthesis (15, 16) . These growth factors bind to heparan sulfate proteoglycans, which in turn may protect and potentiate them (17) (18) (19) (20) .
We recently developed a family of pharmacological agents called ReGeneraTing Agents (RGTA), which are polymers engineered to mimic the protective and potentiating properties of heparan sulfates toward heparin-binding growth factors (HBGF) such as FGF-2 and TGF-β1 (21) (22) (23) . Furthermore, RGTAs promote in vivo repair of several tissues (24) (25) (26) (27) and in vitro modulation of collagen expression by mesenchymal cells (8-10, 23, 28) . These polymers mimic the antiproliferative effect of heparin on SMCs but have no anticoagulant activity (10, 21).
We described previously two RGTA polymers (see Fig. 1 for detailed structures) regarding their differential regulating effects on collagen III and collagen V synthesis by SMCs. RG-1503, a carboxylmethylsulfate dextran, increased collagen V production, whereas RG-1192, a carboxylmethylsulfate dextran with additional benzylamide substitution, reduced collagen III production (10, 23) . Drugs that selectively regulate the collagen phenotype may prove valuable for treating collagen-deposition vascular disorders. RGTAs exhibit a combination of favorable properties. They inhibit SMC proliferation, have no significant anticoagulant activity, and modulate the collagen phenotype. An essential step is to understand more thoroughly how collagen type expression could be modulated by these potential pharmacological agents, thereby providing a rationale for designing drugs adapted to specific vascular disorders.
In this objective, we investigated the possibility that benzylamide-containing RG-1192 modulates collagen expression via interaction with FGF-2, whereas RG-1503, without benzylamide moiety, differently influences collagen synthesis via interaction with TGF-β1. The significant bioactivity of these two heparan sulfates mimetics was compared with the limited efficacy of heparin on collagen synthesis.
T MATERIALS AND METHODS

Materials
Chemicals for cell cultures, media, and sera were purchased from Gibco BRL (Paris, France). All other reagents were obtained from Merck (Darmstadt, Germany) or Sigma (St. Louis, MO). FGF-2, FGF-2 neutralizing antibody, FGF-2 specific ELISA (Quantikine test), TGF-β1, and TGF-β1 neutralizing antibody were from R&D Systems (Abington, UK). Porcine intestine heparin (CY-108, average M r 12000; specific anticoagulant activity 173 IU/mg) was kindly provided by Sanofi (Paris, France). The BIAcore TM instrument, CM5 sensor chip, and chemicals for plasmon surface resonance analysis were acquired from Amersham Pharmacia Biotech (Uppsala, Sweden).
RGTA preparation
The water-soluble dextran derivatives RG-1503 and RG-1192 (see Fig. 1 for detailed structures) were prepared from T40 dextran (average M r 37000; Pharmacia) as described previously [29] . Briefly, for RG-1503, carboxymethyl dextran was synthesized from dextran T40 by carboxymethylation of OH residues with monochloracetic acid treatment. The presence of carboxymethyl groups was confirmed by infrared spectroscopy, which showed an absorption band at 1650 cm -1 . Then, RG-1503 was obtained from carboxymethyl dextran by O-sulfonation. The presence of sulfate groups was indicated by infrared spectroscopy, with the appearance of two absorption bands at 1250 and 1025 cm -1 , respectively. For RG-1192, the carboxymethyl dextran was dissolved in H 2 O/EtOH, and carboxylate functions were activated with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline for 30 min at pH 3.5 and room temperature. After overnight incubation with 2 eq of free benzylamide, the product was precipitated and washed with methanol then dried under a vacuum. The infrared spectrum confirmed the presence of benzylamide with the appearance of a new absorption band at 1750 cm -1 , corresponding to the carbonyl bond of the amide. RG-1192 was synthesized from the derivatized carboxymethylbenzylamide dextran by O-sulfonation. The presence of sulfate groups was indicated by infrared spectroscopy, with the appearance of two absorption bands at 1250 and 1025 cm -1 , respectively.
Chemical characterization of RG-1503 and RG-1192 was based on the degree of substitution (d.s.) of each individual group per glucosidic unit ( Fig. 1) . A d.s. value of 3 indicates maximum substitution, as one glucosidic unit contains three reactive OH groups at the C2, C3, and C4 positions. Each d.s. value was determined by acidimetric titration and elementary analysis and confirmed by 1 H-nuclear magnetic resonance. The distribution of the three reactive OH groups is reported in Fig. 1 . Average molecular weights of the RGTA molecules were estimated by highperformance size-exclusion chromatography as described previously [30] . These polymers did not show significant anticoagulant activity (less than 5 IU/mg as compared with 173 IU/mg for heparin).
Cell culture
SMCs were grown from newborn pig aorta media explants, in Dulbecco's modified Eagle's minimal essential medium (DMEM) supplemented with 20% fetal calf serum (FCS), 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2 mM glutamine (10). Confluent SMC cultures demonstrated the characteristic hill-and-valley growth morphology. Viability of cells in the presence of RGTA was tested by lactic dehydrogenase determination (EC 1.1.1.27).
Collagen biosynthesis
In all biosynthesis experiments, SMCs serially passaged with 10% FCS up to the third subculture were used at post-confluence in serum-free medium to eliminate or minimize a contribution to the study results of cell proliferation changes induced by RGTA or growth factors (10). Under these conditions, no significant variations in cell numbers were detected during the experimental period. As described previously (26) , cells were incubated for 24 h in serum-free culture medium containing (5 3 H) proline (25 µCi/ml; 30 Ci/ml; Amersham-France) and ascorbic acid (50 µg/ml) without effector or with RGTA (4 to 1000 µg/10 6 cells), with heparin (in the same molar concentration range as RG-1192, namely, 0.35 to 86 µg/10 6 cells), and with FGF-2 or TGF-β1 (0.1 to 10 ng/10 6 cells).
FGF-2 neutralizing antibody was used at 10 µg/ml, according to (14) and to the manufacturer's recommendations. At the end of labeling, the medium and cell layer were collected and dialyzed against distilled water at 4°C. Medium and cell dialysates were digested with pepsin, and collagen phenotypes were determined by SDS-PAGE (31) . The relative proportions of radioactivity incorporated in collagen I, collagen III, and collagen V were determined as described previously (31) . Briefly, collagen α-chains separated on SDS-PAGE were quantified by excision of the individual collagenous bands, hydrolysis of each band in 6N HCl at 105°C for 24 h, and determination of hydroxy( 3 H)proline in the hydrolysate.
RNA analysis
Total RNAs were extracted from cells by guanidium isothiocyanate (32) . RNA purity and integrity were checked, based on the A 260 /A 280 ratio and on agarose gel electrophoresis results. For quantitative assessment, RNA was subjected to Northern blot analysis. Briefly, a defined amount of RNA (10 µg) was separated by electrophoresis in 1% agarose formaldehyde gel then blotted onto nylon filters (Hybond N+, Amersham-France). Northern blots were prehybridized at 42°C for 24 h in solution A containing 50% (v/v) formamide; 5× saline sodium citrate buffer (SSC; 1× SSC: 0.15M NaCl, 0.015M sodium citrate, pH 7.0); 0.5% SDS; 0.1% each of Ficoll, polyvinylpyrrolidone, and BSA; and 200 µg/ml of heat-denatured sonicated herring-sperm DNA. Hybridization was performed in fresh solution A, containing 3-5 × 10 8 cpm/mg of the appropriate 32 P-labeled probes, for 24 h at 42°C. Labeling was performed by using the random primer procedure with a commercial kit (Amersham-France). Hybridization was followed by two 30-min washes in 2× SSC, 0.1% SDS; two 20-min washes in 1× SSC, 0.1% SDS; and two 15-min washes in 0.1× SSC, 0.1% SDS. The filters were exposed to X-ray film at 80°C. The autoradiograms were quantified by densitometric scanning by using a laser densitometer (Ultrascan LKB-France). The following cDNA probes were used: Hf677 specific for human α1(I) collagen (33), Hf934 specific for human α1(III) collagen (34) , and HT168 specific for human α1(V) collagen (35) , all from American Type Culture Collection (Manassas, VA); and GAPDH (glyceraldehyde-3-phosphate-dehydrogenase) probe provided by C. Chapel (CEASaclay, France; 36).
Quantification and compartmentalization of FGF-2
For determination of total endogenous FGF-2 and its cellular distribution, post-confluent cultured SMCs were processed as described previously (12). Briefly, the serum-free medium of cultured SMCs was removed and the cell layer was trypsinized (0.05% trypsin, 0.02% EDTA in PBS). After addition of soybean trypsin inhibitor, the cells were centrifuged and the supernatant, which contained the pericellular FGF-2, was examined by using a specific ELISA (Quantikine test, R&D Systems, Abington, UK). Intracellular FGF-2 was obtained from trypsinized cells by lysis with 2 M NaCl, 1% Triton ×100, pH 5.5, then quantified by using the same specific ELISA. As a control, total cell-associated FGF-2 was measured on a direct lysate of the cell layer, without trypsin treatment.
CCL39 bioassay for FGF-2 activity
FGF-2 activity was determined as described previously (21, 22) . Briefly, Chinese hamster lung fibroblasts (CCL39 obtained from ATCC) were cultured in DMEM containing 10% FCS. Before confluence, the culture medium was replaced by serum-free medium for 24 h. Then FGF-2 (0.1-5 ng/ml) was added, followed 20 h later by 1 µCi of ( 3 H)-thymidine (2 Ci/mM; AmershamFrance). Four hours later, the increase in CCL39 growth was measured.
Ability of RG-1192 to protect FGF-2 activity from proteolysis
The ability of RG-1192 to protect FGF-2 activity from proteolysis was evaluated by assaying FGF-2 activity following exposure to purified protease (21, 22) . Proteolytic degradation was monitored, based on loss of FGF-2 activity in the CCL39 bioassay described above. Briefly, FGF-2 (5 ng/ml) was pre-incubated with RG-1192 (400 µg/ml) or heparin (35 µg/ml) for 30 min at 37°C. Trypsin (50 µg/ml) was added for 120 min. Proteolysis was stopped by adding trypsin inhibitor. Aliquots of the reaction mixture were added to wells containing CCL39, and FGF-2 activity was quantified as described above.
Surface plasmon resonance analysis
Biotinylation of RG-1192 and heparin
Polysaccharides were labeled by reaction of their aldehydic reducing group with the hydrazide functional group of biocytin hydrazide (BCH) as described previously (29) . Briefly, 15 mg of polysaccharide was dissolved in 50 µL of formamide containing 50 mM of BCH and heated at 37°C for 24 h. Free BCH and formamide were removed by gel filtration chromatography, and homogeneity of the labeled polysaccharides was checked by gel permeation chromatography (TSK gel G4000 PWXL).
Preparation of sensor surfaces
The immobilization procedure was performed at 25°C in 10 mM HEPES, pH 7.4; 150 mM NaCl; 1 mM EDTA; and 0.005% P-20 (HBS buffer), at a constant flow rate of 5 µl/min, according to the BIApplications handbook (Amersham Pharmacia Biotech). A mixture of 0.1 M Nhydroxysuccinate/N-ethyl-N'-(3-diethylaminopropyl) (25 µL) carbodiimide hydrochloride (NHS/EDC) was injected over the surface of a CM5 sensor chip, followed by 50 µl of streptavidin (200 µg/ml in 10 mM sodium acetate, pH 4.5) then by 25 µl of ethanolamine to block remaining active carboxyl groups. Biotinylated polysaccharide (10 µL; RG-1192 or heparin 1 mg/ml) was injected on the streptavidin-immobilized surface, followed by two pulses of 10 nM HCl to remove non-covalently attached ligand. The amount of polysaccharide immobilized on the surface was 100 resonance units.
Determination of the equilibrium dissociation constant
Binding reactions were performed at a flow rate of 10 µl/min at 25°C. Various concentrations of FGF-2 in HBS buffer were injected over the polysaccharide-immobilized surface, and changes in the resonance signal over time were monitored. The same volume of FGF-2 was injected over a streptavidin-immobilized surface to serve as a blank for subtraction of non-specific analyte binding. The sensor surfaces were regenerated with 2M NaCl between each injection of analyte. The equilibrium dissociation constants were determined as described in the BIAtechnology handbook (Amersham Pharmacia Biotech). At steady state,
which can be rearranged as follows:
where
is the equilibrium dissociation constant, R eq is the response value at the steady state, R max is the maximal capacity of the sensor chip for binding the analyte, and C is the molar concentration of the analyte. K d was calculated by non-linear regression analysis by fitting the (R eq , C) pairs to Eq. 2 using GraphPad Prism software.
Statistical analysis
The results are expressed as the means (± SD) of the specified number of independent determinations performed on different SMC cultures in triplicate. Differences between the means in two groups were evaluated by using Student's paired t-test; P values <0.05 were considered significant.
RESULTS
To separate potential influences of RGTA, heparin, FGF-2, and TGF-β1 on biosynthesis by SMCs from their influences on cell proliferation, these compounds were incubated with serumfree, post-confluent cell cultures for 24 h. During this period, no significant proliferation was observed in control or treated cells; SMC morphology and viability remained unaltered.
Effect of RGTA, heparin, FGF-2, and TGF-β1 on collagen biosynthesis by SMCs
Total protein synthesis was not affected by RGTA, heparin, or growth factors, in keeping with earlier data (10; data not shown) RG-1192 induced an 80% decrease in collagen III expression by SMCs at the maximum-efficacy dose of 400 µg/10 6 cells ( Fig. 2A) . This decrease was specific: The biosynthesis of the other fibrillar collagens was not significantly altered by RG-1192. Heparin in equivalent molar concentrations as RG-1192 was significantly less effective in diminishing collagen III production (up to 46% decrease; Fig. 2B ). FGF-2 also specifically decreased collagen III production (up to 45%; Fig. 2C ). The decrease in collagen III production, obtained with RG-1192 ( Fig. 2A) was totally abolished by neutralizing FGF-2 antibody at 10 µg/10 6 cells. By contrast, the heparin-induced diminution in collagen III (Fig. 2B) was not significantly altered by this antibody (data not shown).
For comparison, RG-1503 (Fig. 2D) and TGF-β1 (insert from Fig. 2D ) specifically increased collagen V production, as described previously for both compounds (23) .
When used together, RG1192 and FGF-2 demonstrated a cooperative effect in decreasing collagen III synthesis (Fig. 3) . For example, while the maximum decrease of collagen III production was obtained with RG1192 alone at a concentration of 400 µg/10 6 cells, a concentration of only 40 µg/10 6 cells in combination with FGF-2 at 2 ng/10 6 cells induced a decrease in collagen III synthesis to a value close to the lowest value obtained (29 vs. 22%; Fig.  3 ).
When heparin (at 86 µg/10 6 cells) was used together with FGF-2 (at 10 ng/10 6 cells), no evidence of a comparable cooperative effect was found (Fig. 4) . Preliminary experiments showed that T40 dextran, carboxylmethyl dextran, and carboxymethylbenzylamide dextran (up to 1000 µg/10 6 cells) had no significant activity on collagen III synthesis (nor on other collagen types) by SMCs (Fig. 4 ).
For comparison with the cooperative effect of RG-1503 and TGF-β1 on stimulation of collagen V production, we report here an extension of our previous study (23) , which showed a strong interaction between these two effectors (Fig. 5) . Heparin added to TGF-β1 under the same conditions induced no further modification in collagen V synthesis (data not shown). Adding to the specificity of these interactions between a given RGTA and a given growth factor, no significant cooperation on collagen type production was found between RG-1192 and TGF-β1 or between RG-1503 and FGF-2 (data not shown).
Effect of RG-1192 and FGF-2 on collagen gene expression by SMCs
To clarify the mechanism by which RG-1192 and FGF-2 altered collagen metabolism in SMCs, we measured steady-state collagen mRNA levels by Northern blot. Fig. 6 shows a typical Northern blot analysis of collagen mRNA extracted from treated or untreated SMCs, and reports the densitometry analysis of these Northern blots. No significant differences were found compared with the GADPH probe used as a control. RG-1192 specifically decreased collagen III mRNA levels, in accordance with its effect on the collagen III protein level. FGF-2 specifically decreased collagen III mRNA, to the same extent as collagen III protein. In addition, FGF-2 antibody totally abolished the activity of RG1192 on collagen III mRNA.
Quantification and compartmentalization of endogenous FGF-2 in SMCs
At post-confluence, cultured SMCs expressed FGF-2 in a concentration of 321 ± 47 pg/10 5 cells. Of the total FGF-2, 86% (257 ± 38) was intracellular and 16% (48 ± 7) pericellular. Adding RG-1192 (400 µg/ml for 24 h) significantly increased by twofold the proportion of pericellular FGF-2 (up to 34%: 109 ± 16 pg/10 5 with P<0.05) without changing the total cell layer-associated FGF-2 (338 ± 55 pg/10 5 ). No FGF-2 was detectable in SMC serum-free medium in any of the experiments.
Protection of FGF-2 activity by RG-1192
To further clarify RG-1192/FGF-2 interactions, we looked for a protective effect of RG-1192 on FGF-2 bioactivity. FGF-2 was treated with trypsin at 37°C prior to measurement of FGF-2 bioactivity based on stimulation of CCL39 proliferation. As indicated in Table 1 , trypsin induced a decrease by as much as 84% in FGF-2 activity. RG-1192 abolished this FGF-2 degradation almost completely. Heparin had a similar effect. RG-1192, trypsin, or heparin alone had only minimal effects on the assay results under our experimental conditions.
Surface plasmon resonance analysis of FGF-2 binding to RG-1192
Surface plasmon resonance performed on a BIAcore system was used to confirm the interaction between FGF-2 and RG-1192. The biotinylated polymer was immobilized to a streptavidinbound sensor chip and was used to determine the equilibrium dissociation constant of the FGF-2-RG-1192 complex. Increasing concentrations of FGF-2 were injected over the sensor surface, and surface plasmon resonance values were reached at the steady state, representing the equilibrium binding of FGF-2 to immobilized RG-1192. The equilibrium dissociation constant (K d ) was calculated by non-linear least-square fit of the data to Eq. 2, as described in Materials and Methods. The quantitative results indicated that RG-1192 had similar affinity for FGF-2 as did heparin: 15.7 ± 2.2 nM and 10.6 ± 1.4 nM respectively (means of three independent experiments performed in triplicate).
DISCUSSION
Vascular SMCs synthesize a complex extracellular matrix according to a highly regulated process. This process is altered during the development of atherosclerosis, restenosis, and other vascular disorders. During the atherosclerotic process, SMCs produce an overabundance of extracellular matrix, composed chiefly of collagen III in the early stages than of collagens I and III, which are the main constituents of the fibrotic plaque (5).
We previously developed a family of pharmacological agents, which we called RGTAs, by derivation from dextran via controlled chemical substitutions. Two RGTAs were used in this study: RG-1503, a carboxylmethylsulfate polymer, and RG-1192, a carboxylmethylsulfate polymer with added benzylamide groups. These polymers enhanced tissue remodeling in vivo (24) (25) (26) (27) and were devoid of significant anticoagulant activity. In vitro, they inhibited SMC proliferation. Independently from this effect, that is, with non-proliferating confluent SMCs, RG-1192 preferentially decreased fibrillar collagen III production, whereas RG-1503 selectively increased collagen V production (10, 23). Interestingly, these results suggest that RGTAs with different structures, that is, presence or absence of hydrophobic benzylamide groups, may exert different effects on the collagen phenotype. Furthermore, RGTAs potentiated or formed complexes with heparin binding growth factors such as FGF-2 or TGF-β1 (21) (22) (23) . Among several factors that may influence SMC behavior during the course of atherosclerosis, FGF-2 and TGF-β1 may play a pivotal role in altering the production of collagen by these cells (7, 14, 15, 37). These data prompted us to look for mechanisms by which RGTAs may interact with FGF-2 and TGF-β1 to modulate the types of collagen produced by SMCs. Recently, we demonstrated that RG-1503, which has no benzylamide groups, interacted closely with TGF-β1 to stimulate collagen V production (23) . For comparison, we extended this previous study and found that RG-1503 and TGF-β1 acted cooperatively to increase collagen V production (Fig. 5) .
We also found that RG-1192, which contains benzylamide groups, selectively decreased collagen III biosynthesis by SMCs, in a dose-dependent manner. FGF-2 alone also specifically decreased collagen III expression, in keeping with earlier findings (14), but this effect was only half that of RG-1192. This specific alteration in collagen III synthesis suggests that distinct regulatory pathways may be involved for collagen I and collagen III in arterial SMCs (38, 39) . Our evaluation of the RG-1192/FGF-2 interaction shows that RG-1192 and FGF-2 in combination display significant synergy in stimulating collagen III expression (Fig. 3) . No such effect was demonstrated when heparin was added to FGF-2 (Fig. 4) .
On the other hand, FGF-2 antibody inhibited the selective collagen III decrease induced by RG-1192, at both the protein and the mRNA levels, indicating that endogenous FGF-2 expressed by cultured SMCs possibly mediated the effect of RG-1192 on collagen III expression. In keeping with this possibility, endogenous FGF-2, produced in vitro by post-confluent SMCs, was confined to the pericellular and intracellular compartments in the present study and in earlier work (12). The FGF-2 in this location may represent a pool of endogenous FGF-2 that could interact with and be protected by RG-1192. In our study, RG-1192 significantly increased the relative proportion of pericellular FGF-2 without changing the total amount of cell layerassociated FGF-2. Thus, RG-1192 seems to act essentially by increasing the protected form of FGF-2, rather than by modulating total FGF-2 expression. RG-1192 activity on FGF-2 appears quite different from the stimulation of total FGF-2 expression that had been suggested for heparin (12). Pericellular FGF-2, acting through a FGF-2 receptor-mediated pathway, may be more effective than intracellular FGF-2 in regulating collagen synthesis (40) . In addition, we found that RG-1192 protected FGF-2 from proteolytic degradation (Table 1) . Thus, just as heparan sulfate proteoglycans can bind to and concentrate cytokines at appropriate cellular sites, thereby enhancing the emission by those cytokines of signals to their receptors (41), RG-1192 may increase the local accumulation of endogenous FGF-2, which apparently mediates the effect of RG-1192 on collagen III expression.
Using surface plasmon resonance analysis, we found that the binding affinity of FGF-2 for RG-1192 (K d =15.7 nM) was not very different from that for heparin (K d =10.6 nM). Our results indicate greater affinity than suggested by previously published data on the heparin/FGF-2 interaction (K d =74 nM; 42). Moreover, the affinity of FGF-2 for RG-1192 is quantitatively comparable with the physiological affinity of FGF-2 for heparan sulfate proteoglycans present on the SMC surface (K d =5-50 nM; 43, 44) , further supporting the use of RG-1192 as a functional analog of native heparan sulfates.
The mechanistic results presently reported could be tentatively correlated with the in vivo activity of RGTAs on the speed and quality of healing in various tissues (22, (24) (25) (26) (27) 45) . During healing process, RGTAs seem to limit fibrotic alterations. Collagen III accumulation could be considered as a biological marker for the extent of fibrotic disorders in several tissues (46) . As an extension of the in vitro antifibrotic activity of RGTA, we can establish a parallelism between the RGTA-induced decrease of collagen III production by cultured cells (8-10, 28) and our recent demonstration of the direct diminution of collagen III synthesis in human intestinal tissue from Crohn's disease patients ex vivo exposed to RGTAs (47) . Concerning the mechanism of the growth factor-RGTA interactions implicated in all these processes, we propose that RGTAs may act as a survival and protective agent through the maintenance and protection of the bioavaibility of preexisting and newly synthesized HBGF among those FGF-2 and TGF-β1. These factors are stored on the heparan sulfate moieties of the extracellular matrix. Heparinase is among the first activated enzyme after injury (48) . By cleaving heparan sulfates, heparinase releases the bound HBGF. RGTAs could bind to the heparan sulfate binding sites of the extracellular matrix that had become available after heparinase destruction. Then, RGTAs represent new stable protective sites of binding for HBGF, since RGTAs are less degradable than heparan sulfates by mammalian glycanase (unpublished data).
A generalized application of the RGTA technology could take advantage in a relatively longterm maintenance of HBGF activity in several pathological or accidental tissue injuries where the regeneration of a functional tissue requires a continuous presence of a cocktail of active growth factors and cytokines. Such processes should be involved in most of the in vivo RGTAinduced repairs that we have reported previously in intestine (22) , periodontal tissue (24), oral mucositis (49), bone (25) , muscle (26, 45) , or myocardium (27) . Furthermore, labeled RGTA intravenously injected in a non-injured rat was readily eliminated, whereas in an animal after muscle crushing, RGTA remained only localized in the damaged muscle until regeneration was completed (50) .
Taken together, these data open up new possibilities for developing drugs such as RGTAs characterized by (a) a more rigorously defined chemical structure than the heterogeneous population of heparin molecules; (b) controlled structural variations associated with marked differences in collagen phenotype modulation, as opposed to the modest effect of heparin on collagen III only; (c) significant cooperative activity with FGF-2 (or TGF-β1, depending on RGTA structure), which is not seen with heparin; (d) none of the adverse effects associated with the anticoagulant activity of heparin; (e) a weak degradability by enzymatic activities.
Our data provide a rationale for engineering a range of RGTAs, each adapted to the treatment of a specific collagen deposition-associated disorder. RG-1192 may be particularly well suited for inhibiting the overproduction of collagen that occurs in SMC-related vascular disorders and has been yet found effective in myocardial infarcts (27) and ischemic skeletal muscle (45 Protection of FGF-2 from proteolysis by RG-1192 was analyzed by using a bioassay for FGF-2 activity. FGF-2 (5 ng/ml) was pre-incubated with RG-1192 (400 µg/ml) or heparin (35 µg/ml) for 30 min at 37 °C. Trypsin (50 µg/ml) was added for 120 min, and proteolysis was then stopped by adding trypsin inhibitor. Then, 100 µL aliquots of the reaction mixture were added to wells containing CCL39 in 900 µL culture medium, and FGF-2 activity was determined by stimulation of CCL39 ( 6 cells) for 24 h in serum-free medium. Total RNA was extracted and mRNA analyzed by Northern blot as described in Materials and Methods. Hybridization was performed with ( 32 P)-labeled DNA probes specific for collagen I, collagen III, collagen V, and GADPH. Quantitative data were obtained from densitometric analysis of Northern blot. Results are expressed as relative variations compared with control (arbitrary control value=100 (±SD), determined by cross-comparison among 6 control experiments). No significant variation was observed for the GAPDH probe with or without effectors. Data are the means (± SD) of independent determinations performed in triplicate on three different cell cultures at the third sub-passage. A: control; B: RG-1192; C: FGF-2; D: RG-1192+FGF-2; and E: RG-1192+FGF-2 antibody. *Difference (P<0.05) as compared with control; °difference(p<0.05) between RG-1192 alone and RG-1192+ FGF-2 antibody-treated cells.
